European Hematology Association
Westblaak 71
Rotterdam
3012 KE
Tel: 31-10-404-56-21
Fax: 31-10-436-18-17
Website: http://www.ecah.org/
Email: cme@ehaweb.org
188 articles about European Hematology Association
-
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
5/11/2023
Geron Corporation have been accepted at the European Hematology Association Annual Meeting taking place from June 8-11, 2023 in Frankfurt, Germany and virtually.
-
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
5/11/2023
Cellectis announced the release of an abstract, which was accepted for presentation at the European Hematology Association Hybrid Congress, taking place on June 8-15, 2023 in Frankfurt, Germany.
-
Genmab's Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.
-
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
6/10/2022
Genentech, a member of the Roche Group, announced that it is presenting new long-term follow-up results and subanalyses from clinical trials of its approved therapies, as well as data on investigational medicines from its broad blood cancer portfolio, at the European Hematology Association 2022 Congress in Vienna.
-
Cogent Biosciences shared its Phase II APEX clinical trial on bezuclastinib for patients with AdvSM and showed promise in treating the rare blood disorder.
-
Four Independent Studies of Voraxaze® Published at European Hematology Conference 2022
6/9/2022
The European Hematology Association Conference published four independent studies of Voraxaze® by various investigators for inclusion in its June 2022 EHA Hybrid Congress abstract book and for publication in HemaSphere, EHA’s peer-reviewed, open access journal.
-
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
5/12/2022
Equillium, Inc. announced that the European Hematology Association has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease.
-
Janssen presented the Phase III Glow study for the elderly with CLL or SLL and the overall survival results from the Phase III MAIA study for patients with NDMM.
-
Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini
6/11/2021
Ryvu Therapeutics announced the online publication of two posters and an oral presentation demonstrating clinical and pre-clinical activity of its selective CDK8/19 inhibitor RVU120 and the dual PIM/FLT3 inhibitor SEL24, in-licensed by Menarini Group from Ryvu Therapeutics, at the Annual European Hematology Association 2021 Virtual Congress.
-
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
-
Beigene presented results from three pivotal trials at the 26th EHA2021 Virtual Congress for the effectiveness of their checkpoint inhibitor tislelizumab in relapsed or refractory lymphoma.
-
X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia
5/26/2021
X4 Pharmaceuticals, Inc. announced it will be hosting a conference call and webcast to present and discuss initial efficacy and safety data from the ongoing Phase 1b clinical trial of its lead clinical candidate, mavorixafor, in combination with ibrutinib, in Waldenström’s Macroglobulinemia patients with MYD88 and CXCR4 mutations.
-
EHA25Virtual: Pegcetacoplan, a Novel C3 Complement Inhibitor - Beginning of a New Era in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
6/12/2020
PNH is a rare but severe and usually life-long blood disease in which the blood cells are fragile and easily destroyed by a part of the patient's own immune system, called complement.
-
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
6/4/2020
Protagonist Therapeutics, Inc. announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-thalassemia at the 25th European Hematology Association Annual Congress, which will take place in a virtual format June 11-14, 2020.
-
Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases
5/20/2020
Data from multiple studies, including results in the outpatient administration setting and using machine learning technology, evaluating potential of CAR T liso-cel in relapsed and refractory large b-cell lymphoma
-
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings
6/18/2019
Innovent Biologics, Inc. announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human BCMA CAR-T co-developed by Innovent and Nanjing IASO Biotherapeutics, was presented by oral presentation and poster at two of the most prestigious clinical meetings in the worlds of hematology and oncology, the 24th Congress of the European Hematological Society and the American Society of Clinical Oncology Annual Meeting 2019 in Chicago Illinois.
-
Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology Association
6/18/2019
Company encouraged by interim 13-week data in trial designed to assess the safety and tolerability of IMR-687 and explore the potential efficacy of IMR-687 on clinical outcome measures relevant to sickle cell disease
-
Medigene AG: Interim analysis from ongoing Phase I/II clinical trial with DC vaccines in AML patients presented at EHA
6/17/2019
Medigene AG announced that clinical data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene's DC vaccine for the treatment of acute myeloid leukemia was presented during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
-
Data Presented At 24ᵗʰ Congress of the European Hematology Association Demonstrates Clinical Safety, Early Efficacy of Imago BioSciences' IMG-7289 in Myelofibrosis Patients
6/17/2019
Data Informs Expansion of Study into Phase 2b and Considerations for Clinical Studies of IMG-7289 in Additional Myeloid Diseases
-
New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
6/16/2019
Oncopeptides AB announced updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial.